RHYTHM PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $189.8M | $130.1M | $77.4M | $23.6M | $3.2M |
| Cost of revenue | $19.5M | $13.4M | $9.3M | $2.1M | $599,000 |
| Selling, general & administrative | $194.9M | $144.3M | $117.5M | $92.0M | $68.5M |
| Research and development | $167.3M | $238.0M | $135.0M | $108.6M | $104.1M |
| Operating income | -$192.0M | -$265.5M | -$184.4M | -$179.2M | -$170.1M |
| Interest expense | $20.6M | $20.6M | $13.9M | $5.2M | — |
| Pretax income | -$196.0M | -$260.3M | -$184.1M | -$181.1M | -$69.6M |
| Income tax expense | $497,000 | $346,000 | $564,000 | — | — |
| Net income | -$196.5M | -$260.6M | -$184.7M | -$181.1M | -$69.6M |
| Balance Sheet | |||||
| Cash and equivalents | $54.3M | $89.1M | $60.1M | $127.7M | $59.2M |
| Current assets | $466.9M | $374.2M | $308.3M | $354.2M | $308.4M |
| Total assets | $480.2M | $392.3M | $332.7M | $382.5M | $329.5M |
| Current liabilities | $105.9M | $115.5M | $55.2M | $39.8M | $43.4M |
| Total liabilities | $210.2M | $227.7M | $163.0M | $118.2M | $45.4M |
| Stockholders' equity | $139.1M | $21.7M | $169.8M | $264.3M | $284.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$115.7M | -$113.9M | -$136.2M | -$173.4M | -$146.0M |
| Depreciation and amortization | $500,000 | $700,000 | $900,000 | $896,000 | $816,000 |
| Stock-based compensation | $66.8M | $39.7M | $32.6M | $19.8M | $20.8M |
| Capital expenditure | $953,000 | $0 | $47,000 | $281,000 | $434,000 |
| Free cash flow | -$116.6M | -$113.9M | -$136.2M | -$173.7M | -$146.4M |
| Impairments | — | $0 | $0 | $0 | $0 |
Shares outstanding 68.5M · Free float 88.6%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.